▲Shin Cheol-soo, CEO of AP Technology (left), Nutin Edward Rocket Ventures, CEO of AP Technology, investment contract
Accelerate global business of breast milking new promising materials
AP Technology, a South Korean bio venture, said on the 21st that it has attracted strategic investments from Rocket Group, a French bio-food materials company.
AP Technology is a bio venture that started developing pharmaceutical protein production technology in 2001 and has metabolic engineering, fermentation, and separation refining technologies and experiences at the level of commercialization.
AP Technology completed the HMO Campus in Hwaseong, Gyeonggi Province, with the first investment from domestic venture capital in 2018, and plans to start mass commercial production in earnest from next year.
It is also considering CMO (Contract Manufacturing Organization) contracts or establishment of second-stage large-scale production facilities in preparation for future increase in demand.
France's Rocket Group is a global leader in vegetable materials and proteins, operating in more than 100 countries, with annual sales of €3.3 billion and hiring 8,400 executives and employees worldwide.
"This investment attraction is meaningful in that it has been recognized by global bio-food material companies," said Shin Cheol-soo, CEO of AP Technology. "As Korea has secured production technology of breast milk oligodang, we will maximize import substitution effect and actively expand overseas exports."
It plans to register food ingredients with the Ministry of Food and Drug Safety and the European Food Safety Authority (EFSA) by 2020, and plans to continue to register them in Asia (China, Vietnam, Thailand, India, Russia, Latin America (Brazil, etc.).
AP Technology, meanwhile, is planning to start mass commercial production from next year by completing its HMO Campus in Hwaseong, Gyeonggi Province after receiving 5.5 billion won worth of investment from South Korea's venture capital (KB Investment, Stone Bridge Capital, Intervaluation Partners) in 2018.
Currently, it is pre-marketing with major milk powder and health food companies in Korea, the U.S., and China, and will commercialize consumer products such as Synbiotics, which combines breast milk oligosaccharide and intestinal beneficial bacteria, and Prebiotics, which contain breast milk oligosaccharide.
It also plans to expand its business to cosmetics, medical supplies, household goods, and pet food based on immune activation and harmful bacteria control functions, and further to enter the pharmaceutical market using synergies, immune and brain activation functions with intestinal microbes.
Related Article Shortcuts : http://news.bizwatch.co.kr/article/consumer/2019/10/21/0021